Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16624277 | 0.88 | TDP1 (0.43) | SLC6A3SLC6A4MEN1KMT2AMAPT | |
| SCHEMBL16055062 | 0.85 | MAPT (0.44) | SLC6A3SLC6A4MEN1KMT2AMAPT | |
| SCHEMBL16056314 | 0.85 | SLC6A3 (0.50) | SLC6A3SLC6A4MEN1KMT2AMAPT | |
| SCHEMBL16624224 | 0.85 | SLC6A4 (0.51) | SLC6A3SLC6A4MAPTTDP1ALDH1A1 | |
| SCHEMBL23460477 | 0.83 | MAPT (0.43) | SLC6A3SLC6A4MEN1KMT2AMAPT | |
| SCHEMBL16616262 | 0.82 | SLC6A3 (0.50) | SLC6A3SLC6A4MEN1KMT2AMAPT | |
| SCHEMBL16055343 | 0.81 | LMNA (0.45) | MEN1KMT2AMAPTTDP1ALDH1A1 | |
| SCHEMBL16055476 | 0.81 | SMN1; SMN2 (0.47) | SLC6A3SLC6A4MEN1KMT2AMAPT | |
| SCHEMBL23459274 | 0.81 | SLC6A3 (0.46) | SLC6A3SLC6A4MEN1KMT2AMAPT | |
| SCHEMBL16056201 | 0.80 | SLC6A3 (0.56) | SLC6A3SLC6A4KDM4ECYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113609-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230050965-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. | 2023-02-16 | — | — | US | disclosed |
| EP-4069708-A1 | SSTR5 ANTAGONISTS | Kallyope, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-4069702-A1 | SSTR5 ANTAGONISTS | Kallyope, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-2021113363-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113363-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113368-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113368-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| EP-3055309-B1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-13 | — | — | EP | disclosed |
| US-9751878-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| US-9751878-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3055309-A1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | Takeda Pharmaceutical Company Limited (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-9353108-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-31 | — | — | US | disclosed |
| US-9353108-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-31 | — | — | US | disclosed |
| US-9353108-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-31 | — | — | US | disclosed |
| WO-2015052910-A1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | WO | disclosed |
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113609-A1 | SSTR5 ANTAGONISTS | SSTR5, GLP1R, GPR119 | SLC6A3 337/4885SLC6A4 195/4885MEN1 2406/4885 |
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR4, SSTR2 | SLC6A3 249/4885SLC6A4 145/4885MEN1 379/4885 |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | SSTR5, SSTR4, SSTR2 | SLC6A3 233/4885SLC6A4 139/4885MEN1 383/4885 |
| US-20230050965-A1 | SSTR5 ANTAGONISTS | SSTR5, GLP1R, GPR119 | SLC6A3 337/4885SLC6A4 195/4885MEN1 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.